PRO-105, a phase II open-label study of NUC-1031 in patients with platinum-resistant ovarian cancer.
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2018.36.15_suppl.tps5612
Abstract: TPS5612Background: Patients with platinum-resistant ovarian cancer, following ≥3 lines of chemotherapy have limited treatment options. NUC-1031, a phosphoramidate transformation of gemcitabine, is ... read more here.
Keywords: resistant ovarian; nuc 1031; ovarian cancer; platinum resistant ... See more keywords
Role of BRCA Mutation and HE4 in Predicting Chemotherapy Response in Ovarian Cancer: A Retrospective Pilot Study
Sign Up to like & getrecommendations! Published in 2021 at "Biomedicines"
DOI: 10.3390/biomedicines9010055
Abstract: Even though 80% of patients with High-Grade Serous Ovarian Cancer respond to standard first-line chemotherapy, a majority of them could relapse in the following five years due to a resistance to platinum. Human Epididymis protein… read more here.
Keywords: ovarian cancer; platinum resistant; patients platinum; brca ... See more keywords